Minimal Residual Disease MRD Monitoring for Multiple Myeloma Test
Understanding MRD Monitoring for Multiple Myeloma
Minimal Residual Disease (MRD) Monitoring for Multiple Myeloma represents a revolutionary advancement in cancer care management. This sophisticated diagnostic approach detects microscopic levels of cancer cells that persist after treatment, providing unprecedented insights into treatment effectiveness and disease progression. Multiple myeloma, a cancer of plasma cells in the bone marrow, requires meticulous monitoring to ensure optimal treatment outcomes and prevent disease recurrence.
What is Minimal Residual Disease?
Minimal Residual Disease refers to the small number of cancer cells that remain in the body after treatment, often undetectable by conventional methods. These residual cells can eventually lead to disease relapse if not properly monitored and managed. Our MRD monitoring test utilizes advanced flow cytometry technology to detect these elusive cells with exceptional sensitivity, offering patients and healthcare providers critical information for making informed treatment decisions.
What the Test Measures and Detects
Our comprehensive MRD monitoring test employs multi-parameter flow cytometry to analyze bone marrow samples for specific biomarkers associated with multiple myeloma:
- CD45: Leukocyte common antigen for cell identification
- CD19 & CD20: B-cell lineage markers
- CD27: Memory B-cell marker
- CD38 & CD138: Plasma cell markers critical for myeloma detection
- CD56: Natural killer cell marker often expressed in myeloma
- CD117: Stem cell factor receptor
- CD200: Immunoregulatory molecule
- CD81: Tetraspanin protein
- Kappa & Lambda: Light chain immunoglobulins for clonality assessment
This comprehensive panel enables detection of residual myeloma cells with sensitivity levels reaching 0.01%, providing unprecedented accuracy in disease monitoring.
Who Should Consider MRD Monitoring
This advanced diagnostic test is particularly beneficial for:
- Patients currently undergoing treatment for multiple myeloma
- Individuals who have completed initial therapy and require ongoing monitoring
- Patients experiencing unexplained symptoms despite treatment
- Those with elevated protein levels or other laboratory indicators
- Individuals participating in clinical trials requiring precise disease monitoring
- Patients considering treatment modifications or discontinuation
Symptoms and Clinical Indications
Patients experiencing bone pain, fatigue, recurrent infections, kidney problems, or abnormal blood counts should discuss MRD monitoring with their oncologist. Early detection of residual disease can significantly impact treatment success and long-term outcomes.
Benefits of MRD Monitoring
Choosing our MRD monitoring test provides numerous advantages:
- Early Relapse Detection: Identify disease recurrence before clinical symptoms appear
- Treatment Optimization: Guide therapy decisions based on precise disease status
- Prognostic Information: Assess long-term treatment success and survival probabilities
- Personalized Care: Tailor treatment approaches to individual patient responses
- Clinical Trial Eligibility: Meet stringent monitoring requirements for advanced therapies
- Peace of Mind: Provide reassurance through comprehensive disease monitoring
Understanding Your Test Results
Your MRD monitoring results will provide critical information about your disease status:
MRD-Negative Results
An MRD-negative result indicates that no detectable myeloma cells were found at the current sensitivity level. This typically suggests excellent treatment response and may correlate with improved long-term outcomes. However, continued monitoring is recommended as disease dynamics can change over time.
MRD-Positive Results
Detection of residual disease cells indicates ongoing disease activity. Your oncologist will use this information to adjust treatment strategies, potentially intensifying therapy or considering alternative approaches. The level of MRD positivity can help predict relapse risk and guide timing for additional interventions.
Quantitative Assessment
Results include precise quantification of residual disease, allowing for trend analysis over multiple time points. This quantitative approach enables more nuanced treatment decisions and better prediction of clinical outcomes.
Test Pricing and Details
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $400 |
| Regular Price | $626 |
Sample Requirements and Processing
Sample Type: 3 mL (1 mL minimum) Bone Marrow in Green Top (Sodium Heparin) tube
Turnaround Time: Sample Daily by 9 am; Report 3 Working Days
Storage: Ship immediately at 18-22°C or 2-8°C. DO NOT FREEZE
Required Information
- Sample time point (Chemotherapy time points)
- Previous diagnostic immunophenotype report
- Clinical History (specifically mention if patient is on anti-CD38 therapy)
- Original Test Requisition Form (TRF)
- Date and time when sample was drawn
- 1 or 2 unstained Bone Marrow Aspirate smears made at source
Nationwide Accessibility
We proudly serve patients across the United States with convenient locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our network of specialized collection centers ensures accessible testing for patients nationwide.
Take Control of Your Cancer Journey
Don’t leave your treatment success to chance. Our MRD monitoring test provides the critical information needed to optimize your multiple myeloma management strategy. With rapid 3-day turnaround and comprehensive biomarker analysis, you’ll receive the detailed insights necessary for informed decision-making.
Ready to schedule your MRD monitoring test?
Call our dedicated patient care team today at +1(267) 388-9828 to book your appointment or discuss any questions about the testing process. Our experienced specialists are available to guide you through every step of your diagnostic journey.
Take the next step toward comprehensive cancer monitoring and personalized treatment optimization. Contact us now to schedule your Minimal Residual Disease MRD Monitoring for Multiple Myeloma Test and gain valuable insights into your treatment response and disease status.
